Natera jumps after Signatera CDx wins FDA companion diagnostic approval in bladder cancer

Natera, Inc. (NTRA) is up 5.0% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to a newly announced U.S. regulatory milestone for Signatera CDx, which can expand clinical adoption of Natera’s MRD testing in muscle-invasive bladder cancer. Investors may also be revisiting the company’s recent Q1 update, which highlighted strong test volumes and higher full-year revenue expectations.

Details:

Natera announced that Signatera™ CDx received U.S. regulatory authorization as a companion diagnostic in muscle-invasive bladder cancer, linking MRD-positive status to eligibility for adjuvant atezolizumab therapy.

The U.S. regulator’s approval notice for atezolizumab in this setting also referenced Signatera CDx as the FDA-authorized test used to select patients after cystectomy with ctDNA molecular residual disease.

In its May 7, 2026 Form 8-K, Natera furnished Q1 2026 results and an investor presentation; the update highlighted continued growth in processed test volumes and supported a more optimistic view of 2026 execution.

This could be because traders expect the companion diagnostic label to strengthen payer conversations and reinforce Signatera’s role in treatment decision workflows, improving long-term revenue durability.

Sources:

Natera Investor Relations, U.S. Food and Drug Administration, SEC EDGAR

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$NTRA Insider Trading Activity

$NTRA insiders have traded $NTRA stock on the open market 219 times in the past 6 months. Of those trades, 0 have been purchases and 219 have been sales.

Here’s a breakdown of recent trading of $NTRA stock by insiders over the last 6 months:

STEVEN LEONARD CHAPMAN (CEO AND PRESIDENT) has made 0 purchases and 23 sales selling 194,077 shares for an estimated $44,699,425.
MATTHEW RABINOWITZ (EXECUTIVE CHAIRMAN) has made 0 purchases and 28 sales selling 207,708 shares for an estimated $39,925,592.
MICHAEL BURKES BROPHY (CHIEF FINANCIAL OFFICER) has made 0 purchases and 21 sales selling 79,769 shares for an estimated $18,738,853.
ROELOF BOTHA has made 0 purchases and 11 sales selling 75,000 shares for an estimated $17,708,935.
SOLOMON MOSHKEVICH (PRESIDENT, CLINICALDIAGNOSTICS) has made 0 purchases and 34 sales selling 53,495 shares for an estimated $12,122,271.
HERM ROSENMAN has made 0 purchases and 4 sales selling 48,419 shares for an estimated $11,011,477.
JONATHAN SHEENA has made 0 purchases and 58 sales selling 44,699 shares for an estimated $9,759,305.
DANIEL RABINOWITZ (SEC. AND CHIEF LEGAL OFFICER) has made 0 purchases and 19 sales selling 43,626 shares for an estimated $9,535,071.
JOHN FESKO (PRESIDENT, CHIEF BUS. OFFICER) has made 0 purchases and 10 sales selling 26,137 shares for an estimated $6,047,654.
ROY D. BAYNES has made 0 purchases and 8 sales selling 12,780 shares for an estimated $2,809,688.
ROWAN E CHAPMAN has made 0 purchases and 3 sales selling 4,488 shares for an estimated $1,084,737.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$NTRA Hedge Fund Activity

We have seen 389 institutional investors add shares of $NTRA stock to their portfolio, and 395 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

PRICE T ROWE ASSOCIATES INC /MD/ added 1,312,887 shares (+12.1%) to their portfolio in Q1 2026, for an estimated $262,564,271
JPMORGAN CHASE & CO added 1,225,420 shares (+10.5%) to their portfolio in Q4 2025, for an estimated $280,731,467
FMR LLC added 1,078,266 shares (+73.1%) to their portfolio in Q1 2026, for an estimated $215,642,417
FARALLON CAPITAL MANAGEMENT LLC removed 707,000 shares (-18.1%) from their portfolio in Q1 2026, for an estimated $141,392,930
DUQUESNE FAMILY OFFICE LLC added 552,249 shares (+22.0%) to their portfolio in Q1 2026, for an estimated $110,444,277
D. E. SHAW & CO., INC. added 421,450 shares (+318.9%) to their portfolio in Q4 2025, for an estimated $96,549,980
CASTLE HOOK PARTNERS LP added 361,941 shares (+16.7%) to their portfolio in Q1 2026, for an estimated $72,384,580

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$NTRA Government Contracts

We have seen $470,800 of award payments to $NTRA over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

TUMOR WHOLE EXOME SEQUENCING (WES) AND PERIPHERAL BLOOD CTDNA TEST TESTING (SINGLE ASSAY) SERVICES AND WES ...: $154,100
GENETIC TESTING: $79,200
NEXT GENERATION SEQUENCING AND PERIPHERAL BLOOD CTDNA TESTING SERVICES (RESEARCH): $7,000

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$NTRA Analyst Ratings

Wall Street analysts have issued reports on $NTRA in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

William Blair issued a "Outperform" rating on 04/14/2026
Canaccord Genuity issued a "Buy" rating on 12/22/2025
BTIG issued a "Buy" rating on 12/05/2025
JP Morgan issued a "Overweight" rating on 11/25/2025

To track analyst ratings and price targets for $NTRA, check out Quiver Quantitative's $NTRA forecast page.

$NTRA Price Targets

Multiple analysts have issued price targets for $NTRA recently. We have seen 10 analysts offer price targets for $NTRA in the last 6 months, with a median target of $267.5.

Here are some recent targets:

Mark Massaro from BTIG set a target price of $250.0 on 05/11/2026
Daniel Markowitz from Evercore ISI Group set a target price of $270.0 on 05/08/2026
Brandon Couillard from Wells Fargo set a target price of $220.0 on 05/08/2026
Casey Woodring from JP Morgan set a target price of $265.0 on 05/08/2026
Tejas Savant from Morgan Stanley set a target price of $250.0 on 03/03/2026
Catherine Ramsey from Baird set a target price of $257.0 on 02/27/2026
Patrick Donnelly from Citigroup set a target price of $300.0 on 01/07/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.